SCHEMBL6072373

SCHEMBL6072373

CNC(=O)CCC(=O)Nc1cccc(C2=NC(C)(C)Cc3cc(OC)c4c(c32)CC(C)(C)O4)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.38
POLB P06746 1/20 0.36
NPC1 O15118 1/20 0.35
RAB9A P51151 1/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 3/20 0.35
TSHR P16473 3/20 0.35
HSD17B10 Q99714 3/20 0.35
MEN1 O00255 2/20 0.35
ALDH1A1 P00352 2/20 0.35
MAPK1 P28482 2/20 0.35
HTT P42858 2/20 0.35
NPSR1 Q6W5P4 2/20 0.35
USP2 O75604 1/20 0.34
TP53 P04637 1/20 0.34
HPGD P15428 1/20 0.34
XBP1 P17861 1/20 0.34
HTR1E P28566 1/20 0.34
NTSR1 P30989 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6071835 0.94 MEN1 (0.41) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL6072198 0.94 LMNA (0.37) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL5784678 0.93 LMNA (0.37) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL5786842 0.91 LMNA (0.38) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL5784815 0.91 LMNA (0.36) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL5786230 0.91 LMNA (0.38) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL6071836 0.91 POLB (0.38) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL5784402 0.90 IDO1 (0.37) LMNAPOLBSMN1; SMN2KMT2AMAPT
SCHEMBL5785643 0.90 LMNA (0.35) LMNAPOLBNPC1RAB9ASMN1; SMN2
SCHEMBL5787677 0.89 LMNA (0.37) LMNAPOLBNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060106048-A1 Furoisoquinoline derivative and use thereof PASCALI, PETROS P. (CY) 2006-05-18 US disclosed
EP-1541576-A1 FUROISOQUINOLINE DERIVATIVE AND USE THEREOF Takeda Pharmaceutical Company Limited (JP) 2005-06-15 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060106048-A1 Furoisoquinoline derivative and use thereof PDE3B, PDE2A, PDE3A LMNA 2455/4885POLB 1887/4885NPC1 4713/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.